Category: Research
Clinical Trial of Imfinzi (Durvalumab) in Conjunction with Chemotherapy Yields Significantly Longer Survival Time for Patients Diagnosed with Malignant Pleural Mesothelioma
Immuno-Oncology News recently published results of a Phase 2 clinical trial of the immuno-checkpoint inhibitor Imfinzi (durvalumab) for patients diagnosed with malignant pleural mesothelioma.
The PrECOG cancer research group tested the effects of pairing Imfinzi, an AstraZeneca drug that blocks the activity of the PD-1 receptor in immune T-cells, with standard chemotherapy on a group of 55 individuals who had been recently diagnosed with inoperable malignant pleural mesothelioma. The PD-1/PD-L1 pathway affects inflammation, which causes pleural mesothelioma to develop at a faster rate.
The trial revealed that patients who took Imfinzi in addition to running out courses of standard chemotherapy (pemetrexed with cisplatin or carboplatin) survived for an average of 20.4 months, whereas patients who were given only standard chemotherapy lived for an average of 12.1 months. 81.8 percent of participants were male, their median age was 68, and three-quarters of them had been diagnosed with the epithelioid cancer subtype of malignant pleural mesothelioma.
“[Imfinzi] plus standard chemotherapy delivered a promising median overall survival rate for patients with previously untreated, inoperable malignant pleural mesothelioma,” affirmed Dr. Patrick Forde, director of the Kimmel Center’s thoracic cancer clinical research program, in a news release from the American Society of Clinical Oncology.
AstraZeneca, PrECOG, and the University of Sydney have plans to enroll participants who have been diagnosed with previously untreated, inoperable malignant pleural mesothelioma in a Phase 3 trial in Australia and the United States in September. More details about the upcoming clinical trial can be found here.
If you or a loved one has been diagnosed with mesothelioma, reach out today for a free consultation. Our experts can assist you with medical resources as well as options for compensation from those responsible.
Pairing Machine Learning with PET Scans Can Help Predict Mesothelioma Outcomes
The EJNMMI Research medical journal recently published an article entitled “FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients” that outlines a study wherein 72 patients diagnosed with malignant pleural mesothelioma (MPM) at the University Hospital Zurich underwent pre-treatment FDG PET and CT scans alongside curative treatments. In the study, Swiss researchers discovered that using machine-learning radiomics models in conjunction with PET scans to track tumor progress can help doctors better predict outcomes of malignant pleural mesothelioma.
Malignant pleural mesothelioma is a form of cancer caused by exposure to asbestos and makes up 60 to 70 percent of all cases. MPM occurs when tumors develop in the lining of the lungs and chest cavity (called the pleura).
To obtain imaging that will help them diagnose mesothelioma and prescribe treatment for patients, doctors use both CT scans, which combine several x-ray scans from different angles, and PET scans, which use a radioactive tracing fluid to demonstrate tissue and organ functions.
While they did not have the same results with CT scans, the Swiss research team was able to develop a quantitative model using machine learning to more effectively analyze PET scans and predict the movement of tumors.
Because treating mesothelioma often involves varying approaches and exposes patients to many chemicals, it is critical that doctors are able to determine a course of action for each patient that is most responsive to their individual cancer. Malignant pleural mesothelioma is an aggressive cancer that spreads rapidly, so it is imperative that patients begin receiving treatment as quickly as possible.
If you or a loved one has been diagnosed with mesothelioma, reach out today for a free consultation. Our experts can assist you with medical resources as well as options for compensation from those responsible.
New Study Shows LMB-100 Can Be Even More Effective Paired with Keytruda for Mesothelioma Treatment
A new study published by the Science Translational Medicine journal showed that, for a small cohort, LMB-100 could be even more effective when paired with Keytruda for treating patients with mesothelioma. Researchers saw a median survival rate of almost a year, with a handful of clinical trial participants continuing to show progress after more than three years.
Following this success, the National Cancer Institute is currently accepting clinical trial participants for phase 2 of the study.
LMB-100 is an immunotoxin drug designed to help the immune system find and destroy cancer and mesothelioma cells.
Keytruda, an antibody drug used in cancer immunotherapy manufactured by Merck and also known as Pembrolizumab, has been approved by the FDA over the years for several treatments including solid tumor cancers and non-small cell lung cancer.
The study showed that patients taking both LMB-100 and Keytruda (pembrolizumab) could result in more effective treatment.
“In some of the patients, receiving pembrolizumab after LMB-100 resulted in greater efficacy than what would be expected from pembrolizumab alone,” said Raffit Hassan, M.D., Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute.
Patients diagnosed with malignant mesothelioma are encouraged to speak with their oncologist or consult with a Mesothelioma Center of Excellence to determine whether Keytruda or other medications can be an effective treatment, or whether they might be a candidate for a clinical trial. We at MesotheliomaHelp.org are always available to assist you.
Keytruda Approved by FDA for Further Potential Treatments of Mesothelioma
Keytruda, an antibody drug used in cancer immunotherapy manufactured by Merck and also known as Pembrolizumab, has been approved by the FDA for treatment of solid tumor cancers. Previously, the drug had only been approved to treat non-small cell lung cancer. This is an important development for certain mesothelioma patients.
In a press release, the FDA said that clinical trials showed an effective response rate for 29 percent of patients with mesothelioma and other applicable tumors that displayed high levels of mutation. While there is still no cure for mesothelioma, of those who participated in the trial, half saw a benefit for an additional year, while the other half demonstrated benefit for an additional two years.
The drug works by targeting the cellular pathway of proteins found on the body’s immune cells and some cancer cells. By blocking this pathway, Keytruda may help the body’s immune system fight cancer cells.
The previous FDA approval in 2015 came after a U.S. clinical trial found Keytruda to be effective in controlling mesothelioma tumors in three-fourths of patients, leading researchers to say the results are “encouraging.”
Like lung cancer, pleural mesothelioma is an aggressive cancer that is challenging to treat. Pleural mesothelioma can take decades to display symptoms and can leave patients with life-threatening complications. The asbestos-caused cancer affects the lining of the lungs and often leaves patients with less than 18 months to live after diagnosis.
Patients diagnosed with malignant mesothelioma are encouraged to speak with their oncologist or consult with a Mesothelioma Center of Excellence to determine whether Keytruda can be an effective treatment. We at MesotheliomaHelp.org are always available to assist you.
New Treatment Using Transarterial Chemoperfusion Shows Promise for Mesothelioma Patients
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now